CAR T-cell therapy for systemic sclerosis that hasn't responded to treatment
Part of Immune system & allergy, Skin clinical trials.
This trial tests a new treatment using your own immune cells, modified to attack faulty cells that drive systemic sclerosis. It's for people with active disease who haven't improved with standard therapies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old and weigh at least 40 kg (about 88 lbs).
- You have been diagnosed with diffuse cutaneous systemic sclerosis (widespread skin hardening) within the last 6 years.
- Your skin score is 15 or higher (a measure of skin thickening), and lung scans show inflammation or your lung function is below 70% of predicted.
- You have at least one specific antibody in your blood linked to systemic sclerosis.
- You have tried at least two standard treatments (like immunosuppressants or biologics) for at least 6 months each without enough improvement.
- Your doctors can reduce your steroid dose to allowed levels for the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new CAR-T cell therapy called relmacabtagene autoleucel for people with diffuse systemic sclerosis (scleroderma) that is not responding to standard treatments. The goal is to see if this therapy can help control the disease.
This trial tests a new cell therapy called C-CAR168, which uses a patient's own immune cells to target and potentially reset the immune system to treat conditions like multiple sclerosis, lupus, and myasthenia gravis. It's for people whose disease has not improved with standard treatments.
This trial tests a new type of immune therapy called CAR T-cells that target two markers on your B cells (CD19 and BCMA). It is for people with certain autoimmune diseases that have not improved or have come back after standard treatments. The goal is to see if this therapy can help control the disease.
This trial tests a new CAR-T cell therapy (C-CAR168) for people with several autoimmune diseases that have not responded to standard treatments. It aims to see if this therapy can control the disease when other medicines have failed.
This trial tests a new treatment called CABA-201, which uses your own immune cells to target and calm the overactive immune system causing scleroderma. It aims to reduce symptoms and slow or stop the disease's progression.
This trial tests a new treatment called CAR-T cell therapy for people with severe autoimmune rheumatic diseases that have not improved with other treatments. The therapy uses your own immune cells, which are modified in a lab to attack the cells causing the disease, potentially reducing symptoms and improving quality of life.
Hear when a new Systemic Sclerosis (SSc) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.